The tumor susceptibility gene, TSG101, has been identi®ed as a candidate tumor suppressor gene. We have examined the expression of TSG101 in Burkitt lymphoma cell lines. Several aberrant messages were detected in all cell lines. Aberrant splice donor sites are located within exon 1 at positions 132, 154, 172 and 284. Splice acceptors are located at positions 847 and 1054 within exon 5. The aberrant messages are coexpressed with a normal message and could be the result of additional splicing reactions of the mature message that behaves as an intermediate. The normal message codes for 46 kDa protein (TSG101A). One aberrant message joins in frame nucleotides 283 ± 1055 and codes for a protein isoform of 17 kDa (TSG101B), as demonstrated by in vitro translation assays. The TSG101B isoform lacks the leucine zipper near the C-terminus, a transcriptional repressor domain, and retains most of the N-terminal region which has homology to E2 ubiquitin regulatory enzymes and the CROC-1 transcriptional regulator. The TSG101B isoform was detected in sixteen out of twenty-two (72%) BL cell lines, but not in normal lymphoid populations. The presence of two TSG101 isoforms with dierent dimerization potential opens up a new level of regulation of the TSG101 proteins possibly aecting cell cycle regulation.
Introduction
The tumor susceptibility gene (TSG101) was identi®ed in murine ®broblasts by functional knockout experiments where the resulting phenotype was cellular transformation and ability to form metastasis in nude mice (Li and Cohen, 1996) . This eect was reversed by the introduction of a normal TSG101 function (Li and Cohen, 1996) . On the basis of these experiments it was postulated that TSG101 could represent a new class of tumor suppressor gene (Haber and Harlow, 1997) . The normal TSG101 gene codes for a 46 kDa protein, which has a coiled-coil domain in its carboxy terminus (Li and Cohen, 1996) . This coiled region has been postulated to interact with the oncoprotein-18 or stathmin (Li and Cohen, 1996; Roos et al., 1993) , a cytoplasmic phosphoprotein that appears to relay signals implicated in dierentiation and cell growth, and functions as a transcriptional repressor of the estrogen nuclear receptor superfamily (Watanabe et al., 1998) . However, the function of TSG101 is still unknown. More recently it has been shown that the N-terminal region of TSG101 protein has a highly conserved domain, both in sequence and three dimensional structure (Koonin and Abagyan, 1997; Ponting et al., 1997) , which is homologous to the E2 family of ubiquitin conjugation proteins and the CROC-1/UEV-1 transcriptional regulator of human c-fos (Koonin and Abagyan, 1997; Ponting et al., 1997; Rodofsky and Lin, 1997; Sancho et al., 1988) . But TSG101 has a substitution in place of the active cysteine residue, thus this protein may function as a dominant negative regulator of ubiquitination since it can interact, but not react, with ubiquitination reaction enzymes. This regulation of ubiquitination is very important for cell cycle progression, because it controls the levels of several cyclins (Hershko, 1997) . Thus alterations in the ubiquitination process might be of relevance for oncogenesis, since cyclin regulation by ubiquitination has been shown to aect the G1 to S transition and the anaphase block in the cell cycle (Hershko, 1997; Sancho et al., 1988) .
The human TSG101 gene was recently cloned, it maps to chromosome region 11p15 and codes for a cDNA which is 90% identical to the mouse cDNA (Li and Cohen, 1996; Li et al., 1997) . Aberrantly spliced TSG101 messages with loss of coding exons are frequently detected in breast (Lee and Feinberg, 1997; Steiner et al., 1997) , prostate (Sun et al., 1997) , small cell lung carcinomas (Oh et al., 1998) and acute myeloid leukemia (Lin et al., 1998) . In some cases the aberrant messages might be the result of rearrangements at the DNA level (Lee and Feinberg, 1997; Steiner et al., 1997) . Normal TSG101 protein can be detected with antibodies in breast carcinoma cell lines (Zhong et al., 1997) . These aberrant messages are always coexpressed with a normal transcript in tumor cells (Lee and Feinberg, 1997) , and they are also detectable, albeit at a much lower frequency, in normal cells (Gayther et al., 1997; Lin et al., 1998) . So far there is no evidence that any of these alternatively spliced TSG101 messages can code for a protein, despite the fact that alternative splicing is a well known mechanism in the generation of variant forms of a protein in cell dierentiation and development.
Burkitt lymphomas (BL) represent a well de®ned type of B cell tumor (Ehlin-Henrikson et al., 1987; Magrath, 1990) . These tumors are characterized by a speci®c translocation involving the chromosome band 8q24, where the MYC oncogene is located, and any of the chromosomes containing the immunoglobulin genes. The most common translocation is a t(8;14), but both immunoglobulin light chains are implicated in t(2;8) or t(8;22) translocations (Rabbitts, 1994) . In line with the current thinking that oncogenesis is a multigenic process (Fearon, 1997; Kinzler and Vogelstein, 1996) it is very likely that additional genetic alterations are identi®ed in this type of tumor. Because this tumor is well de®ned, despite variation in type of translocation, presence of Epstein-Barr virus, or type of presentation, sporadic or endemic (Magrath, 1990) , if new genetic changes are found they are likely to be independent of these dierences, because they are related to the common aspects of this tumor phenotype.
In this work we have determined the structure of human TSG101 messages present in Burkitt lymphoma cell lines, because no information is available on this gene in any type of lymphoid tumors. We have identi®ed an aberrant message which codes for a new TSG101 protein isoform, in addition to several noncoding aberrant messages. This isoform lacks the dimerization leucine zipper and retains most of the ubiquitin regulatory homology domain. These observations suggest new possibilities for the role of TSG101 gene products in cell cycle regulation and tumor biology.
Results

Expression of aberrant transcripts in Burkitt lymphomas
To detect the presence of aberrant transcripts in Burkitt lymphoma cell lines we followed an approach similar to that employed for breast carcinomas . cDNA from each cell line was subject to a nested PCR, the relative position of the primers with respect to TSG101 normal message is shown in Figure  1 . The ®rst PCR was performed with primers P1 and P2 and an aliquot of this reaction was reampli®ed using primers P3 and P4 . All cell lines show as RT-PCR products, in addition to a normal size band of 1146 nucleotides, several additional smaller bands (Figure 2 ) that are likely to be derived from aberrant transcripts. One of the shorter bands is common to all cell lines and represent an aberrant transcript resulting from splicing of nucleotides 154 ± 1054 (Lee and Feinberg, 1997; Li et al., 1997; Sun et al., 1997) . Because of the high number of dierent shorter bands, rather than to clone all of them from the dierent cell lines, we decided to clone a wide range of bands from two cell lines, J1 and Namalwa, to cover a wide range of sizes below the normal one and characterize them by nucleotide sequence. In case some particular characteristic could be detected in any of them, then we would proceed to speci®cally search for that speci®c variant in all cell lines in order to determine its frequency in the group of BL cell lines. We therefore cloned seven dierent bands from the J1 and Namalwa cell lines. Also the normal message was cloned and is identi®ed as clone B69. The use of the normal TSG101 cDNA, clone B69, as a probe in Southern blot analysis of DNA from all BL cell lines did not detect any rearrangement or change in relative intensities among the several bands detected (not shown), but we can not rule out larger deletions at the DNA level.
The expression of TSG101 was also studied by Northern blot analysis (not shown). The use of a full length cDNA probe only detected the normal message, but not the other messages corresponding to the aberrant bands observed by PCR. This suggests that all aberrant transcripts are very minoritary messages, and their level of expression is at least one order of magnitude lower than that of the normal transcript. These ®ndings are similar to those reported for other tumors Xie et al., 1998) .
Nucleotide sequence shows that variant cDNAs result from aberrant splicing
The DNA sequence of all cloned aberrant TSG101 messages was determined to identify the type of aberration causing the abnormal size messages. All the bands are the products of alternatively spliced DNA resulting in the loss of internal coding sequences. Normal exon 1 is large and extends from position 1 ± 570, the ATG initiation codon is at position 121. Within this exon there are several splice donor sites (GT dinucleotide) at positions 133, 148, 154 and 285, which are indeed used and all of them are within the normal coding sequence of this exon 1. The most frequently used aberrant splice donor is nucleotide 154 Figure 1 Position of the dierent primers used to amplify dierent regions of the TSG101 cDNA. The primers are shown with respect to the two major domains identi®ed within the normal TSG101 protein. The relative position is related to the normal cDNA and the exact nucleotide position is indicated in the Materials and methods section. URH: ubiquitin regulatoryprotein homology. LZ: leucine zipper or coiled coil region Figure 2 RT ± PCR analysis of RNA from dierent Burkitt lymphoma cell lines. Total RNA from dierent cell lines was converted into cDNA and subject to a nested PCR as previously reported. The short and intense band of 300 nucleotides represents the most common non-coding aberrant message previously reported in other tumors (Lee and Feinberg, 1997; Li et al., 1997; Sun et al., 1997) . jX174 DNA digested with HaeIII was used as size marker within exon 1. The most common splice acceptor site is in nucleotide 1054 within the coding exon 5 (nucleotides 933 ± 1172). This splice acceptor was the most frequently detected in all cell lines. Other splice acceptor sites used in BL are at positions 846 and 933. The common shorter aberrant message detected in all cell lines (Figure 2 ) corresponds to an aberrantly spliced message joining nucleotides 153 ± 1055 (clone A69). Also a common insertion of 42 nucleotides was detected between positions 133 ± 134 in exon 1 in two cell lines, J1 and Namalwa (not shown), which is associated to the 153 ± 1055 splicing variant. The aberrant messages resulting from the fusion of these sequences changed the open reading frame and introduced several in frame termination codons in all cases except one. The message with the 42 nucleotide insertion (clones A68 and A48), between nucleotides 133 ± 134, changes the reading frame introducing several in frame termination codons, therefore it is not a candidate to produce a new protein. We did not detect any point mutation in any of the normal or aberrant cDNA clones sequenced.
However, there is one aberrant TSG101 transcript which results in a correctly spliced message and therefore maintains an open reading frame that could theoretically be translated into a variant TSG101 protein. This aberrant message, caused by the lack of nucleotides 284 ± 1054, results in an in frame fusion. This fusion joins part of exon 1 (nt 283) to part of exon 5 (nt 1055), and the in frame fusion codon codes for an alanine, and at the same time forms a new SacI restriction site within the aberrant cDNA. In Figure 3a we show the normal cDNA sequence with the splice donor and acceptor sites within exons 1 and 5 respectively, and the DNA chromatogram of the aberrant splicing reaction product is shown in Figure  3B .
The alignment of the two TSG101 proteins, normal (isoform A) and the result of aberrant splicing (isoform B) is shown in Figure 4 . The TSG101A normal protein derived from the normal message, contains the ubiquitin regulatory homology domains near the Nterminus (Koonin and Abagyan, 1997; Ponting et al., 1997) and a canonical leucine zipper with seven leucine residues more proximal to the carboxy-terminus. The regions URH1 (ubiquitin regulatory-protein homology 1) and URH2a are the most conserved and speci®c for the E2 ubiquitin inhibitors, while the complete region (URH2 and 3) are homologous with the E2 family of proteins as a group (Koonin and Abagyan, 1997; Ponting et al., 1997) . The TSG101A protein has replaced the active cysteine by a tyrosine in the URH3 region (indicated by an arrow in Figure 4 ), which is a characteristic of E2 inhibitors. The isoform TSG101B codes for a protein that lacks a leucine zipper near the carboxy terminus and retains most of the ubiquitin regulatory domain (Figure 4 ).
In vitro translation of aberrant messages
To demonstrate that the aberrant message which have joined nucleotides 283 ± 1055 in frame can indeed code for altered size proteins, we used an in vitro transcription-translation assay with the T7 DNA polymerase coupled to a rabbit reticulocyte lysate system. We carried out the reaction with clone B69 that has the cDNA coding for the normal size, 46 kD, TSG101A protein ( Figure 5 ). Translation of clones with the in frame splicing 283 ± 1055 variant, C7 (Namalwa) A67 (J1) and A70 (J1) should produce a 
Speci®c detection of TSG101B aberrant message in dierent BL cell lines
The possibility that some of the aberrant transcripts can form a TSG101 protein lacking the dimerization leucine zipper domain (TSG101B) directed us to speci®cally search for the presence of this aberrant message in the panel of Burkitt lymphoma cell lines.
To detect the presence of aberrant transcript coding for the TSG101B protein isoform we followed a PCR strategy based on the use of speci®c primers. The TSG101B messages were detected performing the second ampli®cation with P6 and P7 primers ( Figure  1 ). Using these primers we could avoid most of the other aberrant bands generated from splice donors located before position 284, thus eliminating most of them and simplifying the interpretation of the patterns obtained. The cell lines with the coding aberrant transcript have a band of 255 nt, in addition to the normal band corresponding to the TSG101A message ( Figure 6) . A signi®cant group of cell lines have the expected PCR product that corresponds to the TSG101B isoform, these cell lines are Daudi, Raji, BL60, Namalwa, Maku, BL29, J1, JBL2, Ly66, Ly67, BL2, BL37, BL47, PH3R1, Jijoye and Ramos. Cell lines negative for TSG101B are Ly91, BL41, Ly65, BL28, KK124 and PA682. One of the cell lines, Ly66, has only the aberrant message and no normal message (Figure 6 ), this lack of normal message was con®rmed using other set of primers for PCR ampli®cations. Other aberrant messages are also ampli®ed with these primers in some cell lines, but the size varies among them. Therefore, the aberrant coding TSG101B message was detected in 16 of 22 cell lines or 72% (Figure 6 ). The expected aberrant cDNA coding for TSG101B were con®rmed by DNA sequencing and in vitro transcription-translation assays. In Figure 5 it is shown the protein translation from two of them obtained form the J1 and Namalwa BL cell lines.
Normal cells might do not express the TSG101B isoform
To determine if the detection of the TSG101B isoform message was a characteristic of the tumor cells and not Figure 6 RT ± PCR to search for speci®c aberrant transcripts. Detection of TSG101B transcript in dierent cell lines with primers P6-P7. The reference aberrant transcript was ampli®ed from the clone sequence in order to identify the correct band, because several bands can still be simultaneously ampli®ed with the new primer sets. The aberrant splicing of the bands was con®rmed by DNA sequence analysis. As internal reference we include the PCR performed using the same set of primers on cloned TSG101B, clone A67, from the J1 cell line Figure 7 RT ± PCR analysis of TSG101 transcripts in several normal lymphoid populations from ten dierent normal individuals. Ampli®cation was performed with primers P6-P7 in order to speci®cally identify the band corresponding to TSG101B isoform. As internal reference for this aberrant transcript we include the PCR performed using the same set of primers on cloned TSG101B, clone A67, from the J1 cell line of normal cells, we determined the type of TSG101 messages present in dierent lymphoid organs ( Figure  7) . We used cells from tonsils, and spleen and peripheral blood leukocytes. The results show that in some organs some aberrant non-coding transcript can be detected occasionally, as seen in tonsils 1 and 2 and PBL4 samples, but the band corresponding to the TSG101B isoform was not detected in any of the normal populations studied (Figure 7) .
Discussion
All BL cell lines have splicing aberrations of the TSG101 message. Most of the TSG101 deletions detected in BL and resulting in non coding transcripts are similar to those reported in breast (Lee and Feinberg, 1997; Li et al., 1997; Steiner et al., 1997) , prostate carcinomas (Sun et al., 1997) , small cell lung carcinoma (Oh et al., 1998) and acute myeloid leukemia (Lin et al., 1998) . These splicing aberrations can also be detected in normal cells although at a much lower frequency, suggesting there is a biological selection for them in tumor cells (Gayther et al., 1997; Oh et al., 1998) . Among these, the joining of nucleotides 153 ± 1055 represents the most common and abundant aberrant transcript in all types of tumors breast (Lee and Feinberg, 1997; Li et al., 1997; Lin et al., 1998; Oh et al., 1998; Steiner et al., 1997; Sun et al., 1997) . In this report we have identi®ed a splicing variant that can code for a truncated form of the TSG101 protein, lacking a leucine zipper dimerization domain, that can have biological implications and its presence is detected in 16 of 22 or 72% of the BL cell lines.
Splicing aberrations without apparent DNA deletions is an observation not restricted to TSG101 transcripts. The FHIT gene presents very frequent aberrant splicing aberrations in several types of tumors, mainly carcinomas (Hayashi et al., 1997; Sozzi et al., 1996; Virgilio et al., 1996) . However, these FHIT splicing aberrations result from joining the correct splice donor and acceptor sites of normal exons, most often between a non coding 5' exon and a coding 3' exon, resulting in loss of internal exons (Hayashi et al., 1997; Sozzi et al., 1996; Virgilio et al., 1996) . The FHIT aberrant products most often are an incomplete combination of normal exons and might be a consequence of the physical overlap of this gene with the FRA3B fragile site of chromosome 3 (Zimonjic et al., 1997) . In the case of TSG101, the aberrant splice donor and acceptor sites utilized are within coding sequences, usually in exons 1 and 5. Therefore, this aberrant splicing reaction might occur before the maturation of the normal message, or alternatively result from further processing of the message coding for TSG101A. In both cases, the most common result is the loss of coding potential as a consequence of these deletions. However, there is an aberrant splicing reaction where the joined sequences, nucleotides 283 ± 1055, are in frame resulting in a shorter coding message that might form an additional isoform of TSG101 (form B) which lacks exons 2, 3 and 4, and partially retains exons 1 and 5. This new protein isoform cannot be detected by the available antibody (Zhong et al., 1997) because it was generated against amino acid residues 136 ± 374 of TSG101A which must recognize an epitope comprised within the deleted amino acid residues, 54 and 311, in the TSG101B isoform.
To understand the possible biological role of TSG101 proteins it is necessary to take into consideration the two majors domains already identi®ed within this protein. Based on this information it seems that the N-terminus carries out the TSG101 function, while its carboxy terminus regulates it by modulating its protein-protein interactions. Leucine zippers control dimerization with other proteins and plays an important role in the regulation of several transcription factors (Alber, 1992) . It is not known what other proteins interact with the TSG101A leucine-zipper, although some candidate proteins, all of them implicated in the control of proliferation, such as stathmin and oncoprotein-18 Roos et al., 1993) have been suggested (Li and Cohen, 1996) . However, very recently it has been reported that TSG101A functions as a transcriptional repressor by the interactions of the leucine-zipper, which represses transcription from the estrogen receptor and other members of this nuclear hormone receptor superfamily, as demonstrated by the speci®c deletion of the leucine zipper (Watanabe et al., 1998) . The TSG101B, by losing its zinc-®nger dimerization domain, changes the type of protein interactions that might take place (Alber, 1992) . Therefore, the loss of this region creates a situation where some speci®c protein-protein interactions of TSG101 are no longer feasible and the variant form might have a dierent regulation, or alternatively other genes might have a dierent regulation.
The other possible role of the TSG101A protein is determined by its N-terminal domain. This domain has very high homology, both in sequence and three dimensional structure to the E2 enzymes of the ubiquitin conjugation system, particularly to its negative regulators that have replaced the active cysteine (Koonin and Abagyan, 1997; Ponting et al., 1997) . Within this region there are three blocks of high homology between E2 proteins and TSG101A, part of them are retained in TSG101B (Figure 3) . The physiological consequence of the E2 inhibitory proteins is the formation of a block in the progression of the cell cycle, because they inhibit the ubiquitination of several cyclins (Hershko, 1997) , the alteration of this domain might remove such a block. The ubiquitinrelated homology (URH) region most speci®c for these inhibitors are partially retained TSG101B variant (Figure 3) . Therefore it is likely that the alteration of TSG101 proteins can have consequences for the proliferation phenotype (Sancho et al., 1988) . Also this N-terminus also has homology to a novel transcription factor, CROC-1/UEV-1, which appears to modulate the human FOS gene (Ponting et al., 1997; Rodofsky and Lin, 1997) , and to protect from DNA damage (Thomson et al., 1998) . This might be of biological relevance taking into consideration the role of ubiquitination in cell cycle regulation (Hershko, 1997) . The phenotype of a de®ciency in TSG101A protein results in mitotic abnormalities, such as aberrant spindles and abnormal distribution of chromosomes, suggesting that this gene de®ciency contributes to genome stability (Xie et al., 1998) , consistent with the reported phenotype in yeast, where UEV-1A, a yeast homologue of TSG101 that protects from DNA damage (Thomson et al., 1998) .
The possibility that TSG101 proteins may function as a dominant negative regulator of ubiquitination reactions can have important implications for cell biology. These inhibitors lack the active cysteine which is substituted by other residues, therefore they interact with the ubiquitination E1 enzyme, but because they lack a cysteine they function as inhibitors and are unable to carry ubiquitin to the target protein.
These group of proteins also have an additional region which characterizes them and is present in TSG101 isoforms (Figure 3 ). This dominant negative eect has been demonstrated by site speci®c mutagenesis (Townsley et al., 1997) . Among these proteins are the E2 ubiquitin dependent conjugatory enzymes (Hershko, 1997) . Ubiquitination is needed to target several cyclins for degradation releasing their inhibitory eect and allowing the progression of the G1 to S phase of the cell cycle (Hershko, 1997) . Ubiquitination of cyclin B removes the metaphase block (Hershko, 1997) and allows progression from prophase to metaphase during mitosis (Hershko, 1997) . If normal TSG101A blocks ubiquitination the consequence will be a stop in cell cycle progression. On the other hand the variant forms, TSG101B, by the possible protein associations of the ubiquitin regulatory domain, or changing its structure, might not be able to alter the regulation ubiquitination, and thus permit cell cycle progression by changing its inhibitory potential. From the perspective of tumor biology, the removal of this control point will permit the expansion of the tumor cell population. This is consistent with the observation of an increase in aberrant TSG101 transcripts in carcinoma cells when compared to normal cells (Gayther et al., 1997; Lin et al., 1998) . Other proteins, such as transcription factor NF-kB and retinoblastoma, can also be regulated by ubiquitination. Therefore the regulation of the ubiquitination process can have important consequences for cell cycle regulation, and the phenotype caused by alterations of TSG101 would be consistent with that of other tumor suppressor genes, which also aect cell cycle regulation. This role is consistent with the observed mitotic alterations observed in cells de®cient in TSG101 gene (Xie et al., 1998) .
A tumor cell by regulating the splicing reactions of the TSG101 message can control the formation of additional TSG101 isoforms with deletion of one of the two functional domains of this protein. The formation of TSG101 protein isoforms, if they are implicated in some aspect of tumor biology, such as cell cycle regulation or DNA damage, are likely to be selected for and expanded in the course of the disease.
Materials and methods
Cell lines
The Burkitt lymphoma cell lines were grown in RPMI1640 supplemented with 10% fetal calf serum and antibiotics and incubated in a 5% CO 2 atmosphere. These BL cell lines used in this work are Daudi, Raji, BL60, Ly91, Namalwa, Maku, BL29, BL41, J1, JBL2, Ly65, Ly66, Ly67, BL2, BL32, BL37, BL28, BL47, PH3R1, Jijoye, Ramos, KK124 and PA682 and the lymphoblastoid cell line Bjab. All these cell lines were a gift of Professor Georg Klein (Karolinska Institut, Stockholm, Sweden).
RT ± PCR and DNA sequencing
Total RNA was extracted from dierent cell lines using the guanidinium thiocyanate-cesium chloride method as previously described (Chomczynski and Sacchi, 1987; Feduchi et al., 1994) . We used 5 mg of total RNA used as substrate for cDNA synthesis. As primer for reverse transcription we used an oligo-dT 17 primer and 200 units of Moloney murine reverse transcriptase from Life technologies (Gaithesburg, MD, USA). The cDNA synthesis was performed according to manufacturer's instructions. The ®nal RT product was diluted to a ®nal volume of 50 ml with 1 mM EDTA, 10 mM Tris-HCl, pH 7.2 solution. From this diluted cDNA 1 ml was used for ampli®cation in PCR reactions. For PCR we used the following TSG101 speci®c primers: P1: 5'-CGGGTGTCGGAGAGCCAGCTCAAGAAA-3' (95 ± 120); P2: 5'-CCTCCAGCTGGTATCAGAGAAGTCGT-3' (1260 ± 1285); P3: 5 ' -AGCCAGCTCAAGA A A ATG-GTGTCCA AG -3 ' (106 ± 131); P4: 5 ' -TCACTGA-GACCGGCAGTCTTTCTTGCTT-3' (1126 ± 1252); P5: 5'-TCAGGATCTGTTTGTATAAGGGAGC-3' (1054 ± 1078); P6: 5'-TTAACGATGGCAGTTCCAGGG-3' (221 ± 241); P7: 5'-GAGACCGGCAGTCTTTCTTGC-3' (1228 ± 1248); P8: 5'-CGGCTACTTCTTGATCTAAACGG-3' (915 ± 937); P9: 5'-GGATCTGTTTGTATAAGGGAGCTGTGGG-3' (1048 ± 1075).
To detect the TSG101 derived message we followed the approach previously described . First the cDNA was ampli®ed with primers P1-P2 and 1 ml of the resulting product was reampli®ed either with P3-P4 primers or another pair of primers to detect the dierent species of TSG101 RNA products present in each cell line. The ampli®cation conditions consisted in an initial denaturation cycle at 958C for 5 min followed by 30 cycles consisting of three steps (958C for 45 s; 658C for 30 s and 728C for 1 min) and a ®nal extension at 728C for 10 min. The primer combination used to detect speci®c variants is indicated where appropriate in the results section. To detect the variant TSG101B isoform using primers P6-P7 the annealing was performed at 608C instead of 658C. For ampli®cation we used two units of Thermus Brockianus DNA polymerase (Finnzymes, Oy, Finland) with the buer supplied by the manufacturer. The MgCl 2 was used at 3.6 mM.
Nucleotide sequence
The PCR ampli®ed bands were directly subcloned into the pCR2.1 vector from Invitrogen (San Diego, CA, USA) and sequenced using a Dye Terminator Cycle Sequencing kit (Perkin-Elmer Cetus, Norwalk, CT, USA) using Thermus aquaticus FS polymerase and universal M13-forward and reverse primers. Sequences were resolved in an ABI PRISM 377 automatic DNA sequencer and the results were processed with the ABI Analysis software (version 2.1). The nucleotide sequences were analysed using the PCGene software package from Intelligenetics (Mountain View, CA, USA) or the Omiga 1.0 DNA software from Oxford Molecular (Oxford, UK). As reference of normal TSG101 sequence we used the complete human cDNA sequence with GenBank accession number U82130 .
In vitro translation
The cDNA from aberrant TSG101 transcripts, subcloned in pCR2.1, with the correct orientation with respect to the vector T7 promoter were transcribed and translated in vitro. As substrate for transcription with T7 DNA polymerase we used 0.5 mg of the corresponding plasmid DNA. The transcripts were translated with a rabbit reticulocyte based in vitro assay and labeled with 2 mCi of a 35 S labeled-mix of methionine and cysteine (Promix) from Amersham (Little Chalfont, UK). The coupled transcription-translation reaction was performed according to manufacturer's instructions using a protein truncation test kit, TNT quick coupled transcription/ translation system from Promega (Madison, WI, USA).
The proteins synthesized in this assay were analysed in an SDS-polyacrylamide gel under denaturing conditions.
